Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial

Ray Y Chen, Laura E Via, Lori E Dodd, Gerhard Walzl, Stephanus T Malherbe, André G Loxton, Rodney Dawson, Robert J Wilkinson, Friedrich Thienemann, Michele Tameris, Mark Hatherill, Andreas H Diacon, Xin Liu, Jin Xing, Xiaowei Jin, Zhenya Ma, Shouguo Pan, Guolong Zhang, Qian Gao, Qi Jiang, Hong Zhu, Lili Liang, Hongfei Duan, Taeksun Song, David Alland, Michael Tartakovsky, Alex Rosenthal, Christopher Whalen, Michael Duvenhage, Ying Cai, Lisa C Goldfeder, Kriti Arora, Bronwyn Smith, Jill Winter, Clifton E Barry Iii, Predict TB Study Group, Ray Y Chen, Laura E Via, Lori E Dodd, Gerhard Walzl, Stephanus T Malherbe, André G Loxton, Rodney Dawson, Robert J Wilkinson, Friedrich Thienemann, Michele Tameris, Mark Hatherill, Andreas H Diacon, Xin Liu, Jin Xing, Xiaowei Jin, Zhenya Ma, Shouguo Pan, Guolong Zhang, Qian Gao, Qi Jiang, Hong Zhu, Lili Liang, Hongfei Duan, Taeksun Song, David Alland, Michael Tartakovsky, Alex Rosenthal, Christopher Whalen, Michael Duvenhage, Ying Cai, Lisa C Goldfeder, Kriti Arora, Bronwyn Smith, Jill Winter, Clifton E Barry Iii, Predict TB Study Group

Abstract

Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those without baseline cavity on chest x-ray and whose month 2 sputum culture converted to negative. The 4-month arm relapse rate decreased to 7% but was still significantly worse than the 6-month arm (1.6%, P<0.01). We hypothesize that PET/CT characteristics at baseline, PET/CT changes at one month, and markers of residual bacterial load will identify patients with tuberculosis who can be cured with 4 months (16 weeks) of standard treatment. Methods: This is a prospective, multicenter, randomized, phase 2b, noninferiority clinical trial of pulmonary tuberculosis participants. Those eligible start standard of care treatment. PET/CT scans are done at weeks 0, 4, and 16 or 24. Participants who do not meet early treatment completion criteria (baseline radiologic severity, radiologic response at one month, and GeneXpert-detectable bacilli at four months) are placed in Arm A (24 weeks of standard therapy). Those who meet the early treatment completion criteria are randomized at week 16 to continue treatment to week 24 (Arm B) or complete treatment at week 16 (Arm C). The primary endpoint compares the treatment success rate at 18 months between Arms B and C. Discussion: Multiple biomarkers have been assessed to predict TB treatment outcomes. This study uses PET/CT scans and GeneXpert (Xpert) cycle threshold to risk stratify participants. PET/CT scans are not applicable to global public health but could be used in clinical trials to stratify participants and possibly become a surrogate endpoint. If the Predict TB trial is successful, other immunological biomarkers or transcriptional signatures that correlate with treatment outcome may be identified.

Trial registration: NCT02821832.

Keywords: GeneXpert; MERM; PET/CT; biomarkers; cycle threshold; drug sensitive; pulmonary tuberculosis; treatment shortening.

Conflict of interest statement

Competing interests: No competing interests were disclosed.

Figures

Figure 1.. Predict TB study schematic.
Figure 1.. Predict TB study schematic.

References

    1. WHO: The top 10 causes of death. WHO;2017.
    1. Fox W: Whither short-course chemotherapy? Br J Dis Chest. 1981;75(4):331–357. 10.1016/0007-0971(81)90022-X
    1. Jindani A, Harrison TS, Nunn AJ, et al. : High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–1608. 10.1056/NEJMoa1314210
    1. Gillespie SH, Crook AM, McHugh TD, et al. : Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587. 10.1056/NEJMoa1407426
    1. Merle CS, Fielding K, Sow OB, et al. : A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–1598. 10.1056/NEJMoa1315817
    1. Johnson JL, Hadad DJ, Dietze R, et al. : Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–563. 10.1164/rccm.200904-0536OC
    1. Podewils LJ, Gler MT, Quelapio MI, et al. : Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes. PLoS One. 2013;8(7):e70064. 10.1371/journal.pone.0070064
    1. Liu X, Lewis JJ, Zhang H, et al. : Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med. 2015;12(9):e1001876. 10.1371/journal.pmed.1001876
    1. Mitchison DA, Keyes AB, Edwards EA, et al. : Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle. 1980;61(3):135–144. 10.1016/0041-3879(80)90002-1
    1. Lew W, Pai M, Oxlade O, et al. : Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123–134. 10.7326/0003-4819-149-2-200807150-00008
    1. Pasipanodya JG, McIlleron H, Burger A, et al. : Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464–1473. 10.1093/infdis/jit352
    1. Pasipanodya JG, Srivastava S, Gumbo T: Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55(2):169–177. 10.1093/cid/cis353
    1. Reynolds J, Heysell SK: Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014;10(6):813–823. 10.1517/17425255.2014.895813
    1. Wallis RS, Kim P, Cole S, et al. : Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis. 2013;13(4):362–372. 10.1016/S1473-3099(13)70034-3
    1. Wallis RS, Pai M, Menzies D, et al. : Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet. 2010;375(9729):1920–1937. 10.1016/S0140-6736(10)60359-5
    1. Horne DJ, Royce SE, Gooze L, et al. : Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387–394. 10.1016/S1473-3099(10)70071-2
    1. Phillips PP, Fielding K, Nunn AJ: An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013;8(5):e63840. 10.1371/journal.pone.0063840
    1. Phillips PP, Mendel CM, Burger DA, et al. : Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med. 2016;14(1):19. 10.1186/s12916-016-0565-y
    1. Fox W, Sutherland I: A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q J Med. 1956;25(98):221–243. 10.1093/oxfordjournals.qjmed.a066751
    1. Benator D, Bhattacharya M, Bozeman L, et al. : Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528–534. 10.1016/S0140-6736(02)09742-8
    1. Zierski M, Bek E, Long MW, et al. : Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1980;122(6):879–889.
    1. Yew WW, Chan CK, Chau CH, et al. : Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117(3):744–751. 10.1378/chest.117.3.744
    1. Coleman MT, Maiello P, Tomko J, et al. : Early Changes by Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2014;82(6):2400–2404. 10.1128/IAI.01599-13
    1. Lin PL, Coleman T, Carney JP, et al. : Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis Chemotherapy Regimens. Antimicrob Agents Chemother. 2013;57(9):4237–4244. 10.1128/AAC.00277-13
    1. Carroll MW, Jeon D, Mountz JM, et al. : Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903–3909. 10.1128/AAC.00753-13
    1. Chen RY, Dodd LE, Lee M, et al. : PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014;6(265):265ra166. 10.1126/scitranslmed.3009501
    1. Malherbe ST, Shenai S, Ronacher K, et al. : Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. 2016;22(10):1094–1100. 10.1038/nm.4177
    1. Hesseling AC, Walzl G, Enarson DA, et al. : Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis. 2010;14(5):560–570.
    1. Weiner M, Prihoda TJ, Burman W, et al. : Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol. 2010;48(12):4370–4376. 10.1128/JCM.00757-10
    1. Boehme CC, Nabeta P, Hillemann D, et al. : Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–1015. 10.1056/NEJMoa0907847
    1. Blakemore R, Nabeta P, Davidow AL, et al. : A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med. 2011;184(9):1076–1084. 10.1164/rccm.201103-0536OC
    1. Fennelly KP: An eXpert AFB smear? Clin Infect Dis. 2012;54(3):389–391. 10.1093/cid/cir825
    1. Theron G, Pinto L, Peter J, et al. : The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients. Clin Infect Dis. 2012;54(3):384–388. 10.1093/cid/cir824
    1. Hanrahan CF, Theron G, Bassett J, et al. : Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014;189(11):1426–1434. 10.1164/rccm.201312-2140OC
    1. Friedrich SO, Rachow A, Saathoff E, et al. : Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013;1(6):462–470. 10.1016/S2213-2600(13)70119-X
    1. Shenai S, Ronacher K, Malherbe S, et al. : Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB. PLoS One. 2016;11(8):e0160062. 10.1371/journal.pone.0160062
    1. Brennan AT, Maskew M, Sanne I, et al. : The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013;18(5):619–631. 10.1111/tmi.12079
    1. Kurbatova EV, Cegielski JP, Lienhardt C, et al. : Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3(3):201–209. 10.1016/S2213-2600(15)00036-3
    1. National Tuberculosis Management Guidelines.2014.
    1. Fox W: Whither short-course chemotherapy?. Br J Dis Chest.1981;75(4) :331-57
    1. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis.1989;139(4) : 10.1164/ajrccm/139.4.871 871-6 10.1164/ajrccm/139.4.871
    1. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D: Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis.2010;50(9) : 10.1086/651686 1288-99 10.1086/651686
    1. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D: An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis.2012;55(8) : 10.1093/cid/cis630 1154-63 10.1093/cid/cis630
    1. Nunn A, Anywaine Z, Seeley J, Munderi P, Levin J, Kasirye R, Kamali A, Abaasa A, Grosskurth H: Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda. Contemp Clin Trials Commun.2016;3: 10.1016/j.conctc.2016.05.008 142-146 10.1016/j.conctc.2016.05.008

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner